(BLFS) BioLife Solutions - Ratings and Ratios
Biopreservation, Media, Bioproduction, Tools, Devices
BLFS EPS (Earnings per Share)
BLFS Revenue
Description: BLFS BioLife Solutions
BioLife Solutions Inc (NASDAQ:BLFS) is a US-based company operating in the Health Care Supplies sub-industry. The companys market capitalization stands at approximately $1.18 billion, indicating a mid-cap status. The stocks beta is 1.762, suggesting a relatively high volatility compared to the overall market.
The forward Price-to-Earnings (P/E) ratio is 250, which is significantly high and may indicate that the company is expected to experience substantial growth in earnings. However, the current P/E ratio is not available, and the Return on Equity (RoE) is -1.61%, suggesting that the company is currently unprofitable. Key drivers for the companys stock performance may include revenue growth, profit margin expansion, and the overall demand for its products in the healthcare supplies market.
To evaluate the companys financial health and potential for future growth, key performance indicators (KPIs) such as revenue growth rate, gross margin, operating expenses as a percentage of revenue, and cash flow generation should be closely monitored. Additionally, the companys ability to expand its product offerings, enhance its operational efficiency, and navigate the competitive landscape in the healthcare supplies industry will be crucial in driving its long-term success.
Economic drivers that may impact BioLife Solutions Incs performance include the overall growth of the healthcare industry, regulatory changes, and advancements in medical technology. The companys ability to adapt to these changes and capitalize on emerging trends will be essential in maintaining its competitive position and driving future growth.
BLFS Stock Overview
| Market Cap in USD | 1,212m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1989-11-22 |
BLFS Stock Ratings
| Growth Rating | -16.3% |
| Fundamental | 39.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -14.1% |
| Analyst Rating | 4.78 of 5 |
BLFS Dividends
Currently no dividends paidBLFS Growth Ratios
| Growth Correlation 3m | 73.7% |
| Growth Correlation 12m | -34.3% |
| Growth Correlation 5y | -45.7% |
| CAGR 5y | 1.76% |
| CAGR/Max DD 3y | 0.03 |
| CAGR/Mean DD 3y | 0.09 |
| Sharpe Ratio 12m | 0.14 |
| Alpha | 0.00 |
| Beta | 0.968 |
| Volatility | 53.30% |
| Current Volume | 309.2k |
| Average Volume 20d | 416.3k |
| Stop Loss | 25 (-3.8%) |
| Signal | 0.08 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-5.53m TTM) > 0 and > 6% of Revenue (6% = 4.59m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 7.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 126.9% (prev 55.67%; Δ 71.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 15.5m > Net Income -5.53m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (47.8m) change vs 12m ago 3.90% (target <= -2.0% for YES) |
| Gross Margin 82.67% (prev 22.78%; Δ 59.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 20.08% (prev 27.49%; Δ -7.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.93 (EBITDA TTM -8.07m / Interest Expense TTM 1.07m) >= 6 (WARN >= 3) |
Altman Z'' -10.78
| (A) 0.25 = (Total Current Assets 125.4m - Total Current Liabilities 28.3m) / Total Assets 387.2m |
| (B) -0.91 = Retained Earnings (Balance) -351.4m / Total Assets 387.2m |
| (C) -0.04 = EBIT TTM -14.9m / Avg Total Assets 381.1m |
| (D) -8.76 = Book Value of Equity -351.3m / Total Liabilities 40.1m |
| Total Rating: -10.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.51
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 0.99% = 0.50 |
| 3. FCF Margin 14.96% = 3.74 |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda -2.97 = -2.50 |
| 6. ROIC - WACC (= -13.59)% = -12.50 |
| 7. RoE -1.61% = -0.27 |
| 8. Rev. Trend -39.89% = -2.99 |
| 9. EPS Trend 50.80% = 2.54 |
What is the price of BLFS shares?
Over the past week, the price has changed by -1.59%, over one month by +6.04%, over three months by +16.55% and over the past year by +2.04%.
Is BioLife Solutions a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BLFS is around 24.80 USD . This means that BLFS is currently overvalued and has a potential downside of -4.54%.
Is BLFS a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BLFS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.3 | 20.5% |
| Analysts Target Price | 31.3 | 20.5% |
| ValueRay Target Price | 27.9 | 7.3% |
Last update: 2025-09-05 04:35
BLFS Fundamental Data Overview
CCE Cash And Equivalents = 81.8m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 277.7778
P/S = 12.972
P/B = 3.4595
P/EG = 65.3833
Beta = 1.762
Revenue TTM = 76.5m USD
EBIT TTM = -14.9m USD
EBITDA TTM = -8.07m USD
Long Term Debt = 11.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 24.0m USD (Calculated: Short Term 12.2m + Long Term 11.8m)
Net Debt = -8.09m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (1.21b + Debt 24.0m - CCE 81.8m)
Interest Coverage Ratio = -13.93 (Ebit TTM -14.9m / Interest Expense TTM 1.07m)
FCF Yield = 0.99% (FCF TTM 11.4m / Enterprise Value 1.15b)
FCF Margin = 14.96% (FCF TTM 11.4m / Revenue TTM 76.5m)
Net Margin = -7.23% (Net Income TTM -5.53m / Revenue TTM 76.5m)
Gross Margin = 82.67% ((Revenue TTM 76.5m - Cost of Revenue TTM 13.3m) / Revenue TTM)
Tobins Q-Ratio = -3.29 (set to none) (Enterprise Value 1.15b / Book Value Of Equity -351.3m)
Interest Expense / Debt = 2.85% (Interest Expense 684.0k / Debt 24.0m)
Taxrate = 21.0% (US default)
NOPAT = -14.9m (EBIT -14.9m, no tax applied on loss)
Current Ratio = 4.43 (Total Current Assets 125.4m / Total Current Liabilities 28.3m)
Debt / Equity = 0.07 (Debt 24.0m / last Quarter total Stockholder Equity 347.2m)
Debt / EBITDA = -2.97 (Net Debt -8.09m / EBITDA -8.07m)
Debt / FCF = 2.10 (Debt 24.0m / FCF TTM 11.4m)
Total Stockholder Equity = 343.5m (last 4 quarters mean)
RoA = -1.43% (Net Income -5.53m, Total Assets 387.2m )
RoE = -1.61% (Net Income TTM -5.53m / Total Stockholder Equity 343.5m)
RoCE = -4.18% (Ebit -14.9m / (Equity 343.5m + L.T.Debt 11.8m))
RoIC = -4.15% (NOPAT -14.9m / Invested Capital 358.3m)
WACC = 9.44% (E(1.21b)/V(1.24b) * Re(9.58%)) + (D(24.0m)/V(1.24b) * Rd(2.85%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 1.04%
Discount Rate = 9.58% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.84% ; FCFE base≈11.4m ; Y1≈7.52m ; Y5≈3.44m
Fair Price DCF = 1.11 (DCF Value 53.3m / Shares Outstanding 47.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 50.80 | EPS CAGR: -4.05% | SUE: -2.04 | # QB: 0
Revenue Correlation: -39.89 | Revenue CAGR: -15.77%
Additional Sources for BLFS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle